Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen during controlled ovarian stimulation for fertility preservation in ER-positive breast cancer
NL-OMON36860Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tamoxifen in breast cancer (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Serum endoxifen threshold achievement during controlled ovarian stimulation. Planned start Mar 2013; status: withdrawn.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON36860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36860.